Rapamycin co-exposure fails to reduce cisplatin-induced damage in GC6-spg spermatogonial cell line.
What this study shows
Rapamycin did not protect a mouse spermatogonial cell line from cisplatin damage in vitro, unlike reports in female fertility models.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: GC6-spg spermatogonial cell line) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | GC6-spg spermatogonial cell line |
| Journal | Reproduction & Fertility |
| Year | 2026 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1530/RAF-26-0044 · PMID 42455795 |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Rapamycin |
| Target | mTOR inhibition; spermatogonial stem cell survival |
| Model | Mouse (GC6-spg spermatogonial cell line) |
| Effect | No protective effect – rapamycin does not rescue cisplatin-induced spermatogonial stem cell loss (negative result) |
In the Atlas
Related topics
Was this page useful?
Thank you. Your answer was counted anonymously.